Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838376 | 0.89 | STIM1 (0.41) | GRM5ABL1NPC1RAB9A | |
| SCHEMBL13838426 | 0.88 | ABL1 (0.45) | GRM5ABL1NPC1RAB9AABCB1 | |
| SCHEMBL13728419 | 0.85 | GRM5 (0.42) | GRM5ABL1NPC1RAB9AABCB1 | |
| SCHEMBL13838380 | 0.85 | GRM5 (0.45) | GRM5ABL1NPC1RAB9A | |
| SCHEMBL13838382 | 0.84 | GRM5 (0.45) | GRM5ABL1NPC1RAB9A | |
| SCHEMBL13838359 | 0.84 | NPC1 (0.43) | GRM5ABL1NPC1RAB9ACYP1A2 | |
| SCHEMBL13727537 | 0.82 | ABL1 (0.42) | GRM5ABL1FFAR4 | |
| SCHEMBL13727725 | 0.82 | ABL1 (0.42) | GRM5ABL1NPC1RAB9AABCB1 | |
| SCHEMBL13838319 | 0.81 | IL2 (0.46) | GRM5ABL1 | |
| SCHEMBL13727817 | 0.81 | ABL1 (0.47) | GRM5ABL1NPC1RAB9AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | claimed |
| US-10399967-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2019-09-03 | — | — | US | disclosed |
| US-10399967-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2019-09-03 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20140217016-A1 | BIOMEDIATION METHOD | BIOSTRYKE REMEDIATION PRODUCTS, LLC | 2014-08-07 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2704701-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | GRM5 2918/4885ABL1 4267/4885NPC1 206/4885 |
| US-10399967-B2 | Compounds for inflammation and immune-related uses | CXCL8, CCR1, CCR8 | GRM5 2918/4885ABL1 4267/4885NPC1 206/4885 |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | GRM5 2918/4885ABL1 4267/4885NPC1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.